KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Equity (2016 - 2025)

Nektar Therapeutics (NKTR) has 15 years of Return on Equity data on record, last reported at 3.72% in Q3 2025.

  • For Q3 2025, Return on Equity fell 112.0% year-over-year to 3.72%; the TTM value through Sep 2025 reached 3.72%, down 112.0%, while the annual FY2024 figure was 1.24%, 14.0% down from the prior year.
  • Return on Equity reached 3.72% in Q3 2025 per NKTR's latest filing, down from 22.04% in the prior quarter.
  • Across five years, Return on Equity topped out at 22.04% in Q2 2025 and bottomed at 3.72% in Q3 2025.
  • Average Return on Equity over 5 years is 0.28%, with a median of 1.36% recorded in 2024.
  • The widest YoY moves for Return on Equity: up 2375bps in 2025, down -210bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.71% in 2021, then tumbled by -36bps to 0.96% in 2022, then plummeted by -97bps to 1.89% in 2023, then fell by -15bps to 2.17% in 2024, then plummeted by -72bps to 3.72% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 3.72% in Q3 2025, 22.04% in Q2 2025, and 3.45% in Q1 2025.